Second National Forum on AI in Health: national agenda under construction and 15 CCSS pilot areas
The Second National Forum on AI in Health took place on June 17, 2026, hosted by the Costa Rican Chamber of Health (CCS), the Latin American University of Science and Technology (ULACIT) and the Digital Health Institute for Transformation (DHIT) at the National Auditorium of the Children's Museum in San José. The program featured the official panel 'The AI in Health Agenda: challenges, opportunities and commitments', with participation of Deputy Minister of Health Allan Mora and Elliott Garita, president of the Costa Rican Medical Association. In parallel, an HL7 FHIR R5 Laboratory Results Connectathon was held as a first technical step toward a national clinical-data interoperability guide. Massimo Manzi, executive director of the Costa Rican Chamber of Health (CCS) / PROMED, said the country is close to officializing a national agenda on AI in health, drafted jointly with the Ministry of Health and the Ministry of Science, Innovation, Technology and Telecommunications (MICITT), and warned about balancing regulation and innovation. According to Observador.cr, acting CCSS medical manager Marvin Palma stated that the institution uses artificial intelligence in 15 primary-care pilot areas, including cardiovascular and diabetic risk assessment, and described projects under analysis to identify 'hot zones' in mammograms and other imaging studies. CCSS clarified that AI-assisted waiting-list cleanup keeps a human-validation step before removing any record.
Costa Rica is moving toward a sector-specific framework for AI in health ahead of a general AI framework: the three AI regulation bills (23.771, 23.919 and 24.484) remain uncalled by the executive, while the health sector is pushing its own agenda with executive backing (Deputy Minister of Health on the official panel, Health + MICITT coordination), institutional support from CCSS, from academia (ULACIT) and from an international body (DHIT). The HL7 FHIR R5 Connectathon adds a concrete technical dimension: clinical-data interoperability as a precondition for any large-scale AI rollout. This consolidates a pattern of soft sectoral regulation rather than a cross-cutting framework; it opens advocacy opportunities for sector actors and increases the importance of institutional traceability of the catalogued pilots (AIDA, LIDIA, REDIMED, waiting-list cleanup).